Bank of New York Mellon
IGC icon

Bank of New York Mellon’s IGC Pharma IGC Stock Holding History

Bank of New York Mellon’s Portfolio IGC Stock Details IGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,000
Closed -$4K – 4289
2017
Q2 		$4K Buy
+10,000
New +$4.46K ﹤0.01% 4289

Other funds holding IGC

PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 27.61% 1-Year Est. Return

Bank of New York Mellon's IGC Position: Q3 2017 in Review

Bank of New York Mellon sold out of IGC Pharma (IGC) in Q3 2017, closing a stake of 10,000 shares — an estimated $4K sold.

Bank of New York Mellon first reported a position in IGC in Q2 2017 and held it in 1 quarter. The position peaked at $4K in Q2 2017. 6 funds tracked by Wall St. Rank hold IGC as of Q3 2017.

  • Bank of New York Mellon reported no remaining IGC Pharma position as of Q3 2017 after selling out during the quarter.
  • Bank of New York Mellon sold 10,000 IGC Pharma shares in Q3 2017, an estimated $4K.
  • Bank of New York Mellon first reported a position in IGC Pharma in Q2 2017 and held it in 1 quarter.
  • Bank of New York Mellon's IGC Pharma position peaked at $4K in Q2 2017.
  • 6 funds tracked by Wall St. Rank held IGC Pharma as of Q3 2017.

Based on Bank of New York Mellon's 13F filing for Q3 2017, filed 6 Nov 2017.